Beijing Kawin Technology Share-holding Co Ltd - Asset Resilience Ratio

Latest as of September 2025: 9.90%

Beijing Kawin Technology Share-holding Co Ltd (688687) has an Asset Resilience Ratio of 9.90% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Beijing Kawin Technology Share-holding C (688687) financial obligations for a breakdown of total debt and financial obligations.

Liquid Assets

CN¥284.07 Million
≈ $41.57 Million USD Cash + Short-term Investments

Total Assets

CN¥2.87 Billion
≈ $419.68 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2021–2024)

This chart shows how Beijing Kawin Technology Share-holding Co Ltd's Asset Resilience Ratio has changed over time. See Beijing Kawin Technology Share-holding C net assets for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Beijing Kawin Technology Share-holding Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is Beijing Kawin Technology Share-holding C worth.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥284.07 Million 9.9%
Total Liquid Assets CN¥284.07 Million 9.90%

Asset Resilience Insights

  • Limited Liquidity: Beijing Kawin Technology Share-holding Co Ltd maintains only 9.90% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Beijing Kawin Technology Share-holding Co Ltd Industry Peers by Asset Resilience Ratio

Compare Beijing Kawin Technology Share-holding Co Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Biotechnology 3.28%
Summit Therapeutics PLC
NASDAQ:SMMT
Biotechnology 0.00%
Argen-X
F:1AE
Biotechnology 25.67%
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229
Biotechnology 0.21%
R&G PharmaStudies Co. Ltd. A
SHE:301333
Biotechnology 35.96%
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
Biotechnology 79.48%
Innovita Biological Technology Co. Ltd. A
SHG:688253
Biotechnology 70.49%
Sunmax Biotechnology Co Ltd
TWO:4728
Biotechnology 10.53%

Annual Asset Resilience Ratio for Beijing Kawin Technology Share-holding Co Ltd (2021–2024)

The table below shows the annual Asset Resilience Ratio data for Beijing Kawin Technology Share-holding Co Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 13.41% CN¥350.87 Million
≈ $51.34 Million
CN¥2.62 Billion
≈ $382.75 Million
-1.51pp
2023-12-31 14.92% CN¥365.33 Million
≈ $53.46 Million
CN¥2.45 Billion
≈ $358.25 Million
-8.21pp
2022-12-31 23.13% CN¥511.12 Million
≈ $74.79 Million
CN¥2.21 Billion
≈ $323.35 Million
+19.46pp
2021-12-31 3.67% CN¥80.00 Million
≈ $11.71 Million
CN¥2.18 Billion
≈ $318.67 Million
--
pp = percentage points

About Beijing Kawin Technology Share-holding Co Ltd

SHG:688687 China Biotechnology
Market Cap
$494.29 Million
CN¥3.38 Billion CNY
Market Cap Rank
#12597 Global
#3928 in China
Share Price
CN¥19.76
Change (1 day)
-1.54%
52-Week Range
CN¥19.02 - CN¥38.59
All Time High
CN¥40.56
About

Beijing Kawin Technology Share-Holding Co., Ltd., a biopharmaceutical company, provides treatment solutions for viral and immune diseases in China and internationally. The company offers recombinant human interferon alfa-2b injection; interferon alfa-2b vaginal effervescent tablets; coblopasvir hydrocholoride capsules; sofosbuvir tablets; peginterferon alfacon-2 injection; and compound glycyrrhiz… Read more